Since UBAC2 is a high frequency mutation gene associated with Behcet’s disease, skin, and bladder cancer, the immune dysregulation associated with ER-phagy can be a promising therapy target for further clinical diagnosis and treatment. This evidence concerns the gene UBAC2 and urinary bladder cancer.